miRNAs in Autoimmune Diseases: Contributors or Controllers?
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Published
Apr 30, 2022
Abstract
Even though microRNAs (miRNAs) have been linked to autoimmune diseases, the diagnostic and therapeutic value of miRNAs remains restricted. There is currently no way to determine the function and importance of each miRNA, which makes it impossible to develop targeted medicines and diagnostics for particular diseases. There has been no discovery of a specific miRNA-targeting diagnostic or therapeutic intervention to date.
##plugins.themes.bootstrap3.article.details##
Keywords
miRNAs, Autoimmune Diseases, Diagnostics, Therapeutic Intervention, Prognosis
References
1. Hammond SM. An overview of microRNAs. Adv Drug Deliv Rev 2015; 87:3-14. DOI: https://doi.org/10.1016/j.addr.2015.05.001
2. Aliu O, Chung KC. Assessing strength of evidence in diagnostic tests. Plast Reconstr Surg 2012; 129(6):989e-998e. DOI: https://doi.org/10.1097/PRS.0b013e31824ecd61
3. Baumann V, Winkler J. miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents. Future Med Chem 2014; 6(17):1967-1984. DOI: https://doi.org/10.4155/fmc.14.116
4. Pauley KM, Cha S, Chan EK. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun 2009; 32(3-4):189-194. DOI: https://doi.org/10.1016/j.jaut.2009.02.012
5. Evangelatos G, Fragoulis GE, Koulouri V, Lambrou GI. MicroRNAs in rheumatoid arthritis: From pathogenesis to clinical impact. Autoimmun Rev 2019; 18(11):102391. DOI: https://doi.org/10.1016/j.autrev.2019.102391
6. Tavasolian F, Hosseini AZ, Soudi S, Naderi M, Sahebkar A. A systems biology approach for miRNA-mRNA expression patterns analysis in rheumatoid arthritis. Comb Chem High Throughput Screen 2021; 24(2):195-212. DOI: https://doi.org/10.2174/1386207323666200605150024
2. Aliu O, Chung KC. Assessing strength of evidence in diagnostic tests. Plast Reconstr Surg 2012; 129(6):989e-998e. DOI: https://doi.org/10.1097/PRS.0b013e31824ecd61
3. Baumann V, Winkler J. miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents. Future Med Chem 2014; 6(17):1967-1984. DOI: https://doi.org/10.4155/fmc.14.116
4. Pauley KM, Cha S, Chan EK. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun 2009; 32(3-4):189-194. DOI: https://doi.org/10.1016/j.jaut.2009.02.012
5. Evangelatos G, Fragoulis GE, Koulouri V, Lambrou GI. MicroRNAs in rheumatoid arthritis: From pathogenesis to clinical impact. Autoimmun Rev 2019; 18(11):102391. DOI: https://doi.org/10.1016/j.autrev.2019.102391
6. Tavasolian F, Hosseini AZ, Soudi S, Naderi M, Sahebkar A. A systems biology approach for miRNA-mRNA expression patterns analysis in rheumatoid arthritis. Comb Chem High Throughput Screen 2021; 24(2):195-212. DOI: https://doi.org/10.2174/1386207323666200605150024
How to Cite
Sundjaya, A. C. (2022). miRNAs in Autoimmune Diseases: Contributors or Controllers?. Science Insights, 40(5), 491–492. https://doi.org/10.15354/si.22.co026
Issue
Section
Commentary
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.